These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28947722)

  • 1. [Editorial].
    Özdemir M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):III. PubMed ID: 28947722
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban in Chronic Hemodialysis Patients.
    Muster H; Alcorn H
    Am J Nephrol; 2016; 43(4):227-8. PubMed ID: 27100995
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of rivaroxaban in patients attending a hematology unit in clinical practice.
    Sebastián OG; Fernández MI; Fernández RM; Bernal LP
    Future Cardiol; 2019 Sep; 15(5):347-353. PubMed ID: 31468995
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option.
    Piotrowski R; Zaborska B; Baran J; Sikora-Frąc M; Kułakowski P
    Pol Arch Med Wewn; 2016 Jun; 126(6):430-1. PubMed ID: 27305139
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivaroxaban for thromboprophylaxis in a patient receiving electroconvulsive therapy.
    Shuman M; Hieber R; Moss L; Patel D
    J ECT; 2015 Mar; 31(1):e19-20. PubMed ID: 25587812
    [No Abstract]   [Full Text] [Related]  

  • 9. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device.
    Cohen D
    BMJ; 2015 Dec; 351():h6431. PubMed ID: 26635138
    [No Abstract]   [Full Text] [Related]  

  • 10. The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period.
    Kawai H; Matsushita H; Kawada H; Ogawa Y; Ando K
    Intern Med; 2017 Sep; 56(17):2339-2342. PubMed ID: 28794370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dosing of rivaroxaban is undefined.
    Moore TJ
    BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
    Milling TJ; Spyropoulos AC
    Am J Med; 2016 Nov; 129(11S):S54-S63. PubMed ID: 27569671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: can we trust the evidence?
    Cohen D
    BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102
    [No Abstract]   [Full Text] [Related]  

  • 15. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).
    Suzuki S; Yamashita T; Kasai H; Otsuka T; Sagara K
    Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042
    [No Abstract]   [Full Text] [Related]  

  • 16. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute tubulo-interstitial nephritis due to RIVAROXABAN (XARELTO)].
    Dantec A; Virot JS; Filancia A; Angonin R; Nefti H
    Presse Med; 2017 May; 46(5):541-542. PubMed ID: 28483286
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
    Im SI; Jeong DS; Park SJ; Park KM; Huh J; Kim JS; On YK
    Int J Cardiol; 2015; 186():213-5. PubMed ID: 25828118
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.